Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Caspase 4 (and murine Caspase 11) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Enzyme | Caspase 4 p20/p10 Active Heterodimer / Catalytic Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli expressed. |
View Caspase 4 Products |
| Gene Delivery | Caspase 4 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. |
View Caspase 4 Products |
| Benchmark Ab | Anti-Caspase 4 Recombinant Antibody Recombinant positive control for assay validation (western blot, ELISA). |
View Caspase 4 Products |
| Validator | Caspase 4 siRNA Set For knockdown verification in cell-based pyroptosis assays. |
View Caspase 4 Products |
| Related Target A | GSDMD Direct downstream substrate of Caspase 4; cleavage of GSDMD drives pore formation and pyroptosis. |
View GSDMD Products |
| Related Target B | Caspase 1 Canonical inflammatory caspase; essential for selectivity counter-screening. |
View Caspase 1 Products |
| Related Target C | Caspase 11 Mouse ortholog of Caspase 4; critical for preclinical in vivo translation and efficacy validation. |
View Caspase 11 Products |
| Related Target D | NLRP3 Canonical inflammasome node for parallel pathway screening. |
View NLRP3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Autolytic instability of active Caspase 4 during screening | Catalytically inactive mutant (C258A) available for stable binding and structural studies |
| Subfamily counter-screening (Caspase 1/5/8 selectivity) | Homolog panel of active inflammatory and apoptotic caspases strictly verified by mass spectrometry |
| Preclinical cross-species translation | Human Caspase 4 and Mouse Caspase 11 ortholog proteins available with >95% purity |
| Screening false positives and non-specific inhibitors | Sequence-verified siRNA and clinical benchmark antibodies included for orthogonal validation |
| Active enzyme reconstitution for biochemical assays | Processed p20/p10 subunits co-expressed/purified with >95% purity, endotoxin <1EU/ug |
Live Caspase 4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Caspase 4 (and its murine ortholog Caspase 11) therapeutics is intensifying, with major players shifting focus from broad-spectrum pan-caspase inhibitors to highly selective covalent small molecules targeting the non-canonical pyroptosis pathway. As first-generation therapies reach preclinical and early clinical stages, the next wave of R&D is targeting specific caspase-mediated gasdermin D activation to halt sepsis, inflammatory bowel disease (IBD), acute kidney injury (AKI), and acute respiratory distress syndrome (ARDS). Emerging modalities include targeted protein degradation (PROTACs) to circumvent the conserved active site challenge, and peptide mimetics for acute inflammatory injury.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Covalent Small Molecules | Novartis, Vertex, Pyroptosis Biotechs | Sepsis, IBD, Gout, ARDS | Selectivity Assay (Need mutant C258A vs WT proteins to confirm covalent binding site) |
| Small Molecule Inhibitors (non-covalent) | Novartis, Vertex | Sepsis, ARDS | Enzymatic Assay (Need high-purity p20/p10 active heterodimer) |
| PROTACs / Degraders | Academic Spin-offs, Biopharma | Autoimmune Diseases, Severe Inflammation | Target degradation kinetics (Need high-purity protein for SPR/FP assays; C258A mutant for binding controls) |
| Peptide Mimetics | Therapeutic Start-ups | Acute Inflammatory Injury, Septic Shock | Cleavage inhibition assay (Need active p20/p10 heterodimer and GSDMD substrate) |